News stories about Progenics Pharmaceuticals (NASDAQ:PGNX) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Progenics Pharmaceuticals earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.3747514534717 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news stories that may have impacted Accern’s scoring:

Shares of Progenics Pharmaceuticals (PGNX) opened at $6.12 on Thursday. Progenics Pharmaceuticals has a fifty-two week low of $4.60 and a fifty-two week high of $11.72. The company has a debt-to-equity ratio of 0.80, a quick ratio of 7.86 and a current ratio of 7.86.

Progenics Pharmaceuticals (NASDAQ:PGNX) last announced its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.02. The company had revenue of $2.70 million for the quarter, compared to the consensus estimate of $3.58 million. Progenics Pharmaceuticals had a negative net margin of 445.81% and a negative return on equity of 67.61%. The company’s revenue for the quarter was down 95.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.52 earnings per share. sell-side analysts forecast that Progenics Pharmaceuticals will post -0.92 EPS for the current year.

Several brokerages have recently weighed in on PGNX. BidaskClub raised shares of Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 9th. ValuEngine raised shares of Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, December 7th. Zacks Investment Research downgraded shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, November 8th. Cantor Fitzgerald reissued a “buy” rating and set a $15.00 price objective on shares of Progenics Pharmaceuticals in a report on Thursday, November 2nd. Finally, Needham & Company LLC reissued a “strong-buy” rating and set a $14.00 price objective on shares of Progenics Pharmaceuticals in a report on Friday, September 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $13.75.

ILLEGAL ACTIVITY NOTICE: “Progenics Pharmaceuticals (PGNX) Earns Media Sentiment Rating of 0.13” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/12/14/progenics-pharmaceuticals-pgnx-earns-media-sentiment-rating-of-0-13.html.

About Progenics Pharmaceuticals

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.

Insider Buying and Selling by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.